Comparison
Lanreotid vs. LL-37
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Research other
CAS no.
108736-35-2
597562-32-8
Molecular weight
1096.34 g/mol
4493.33 g/mol
Half-life
no data
no data
Sequence
no data
LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTESMechanism of action
Lanreotid
Lanreotide activates somatostatin receptors (chiefly SSTR2, additionally SSTR5), thereby suppressing the release of growth hormone, IGF-1 and various gastrointestinal and neuroendocrine hormones. It is metabolically far more stable than natural somatostatin.
LL-37
LL-37 is a cationic, amphipathic helical peptide and the only member of the cathelicidin family in humans. It is generated by proteolytic cleavage from the C-terminal portion of the precursor protein hCAP18 (CAP-18). Mechanistically it associates with and can permeabilize microbial membranes; in addition it modulates immune cells, influences cytokine release, exerts chemotactic activity, and can bind extracellular self-DNA. Preclinical models have described both anti-inflammatory and pro-inflammatory effects, depending on concentration and tissue context.
Evidence base
Highest evidence
Human RCT
Human trial
Studies
1
4
of which in humans
1
1
Effects recorded
2
4
Open conflicts
1
1
Documented adverse events
2
0
Legal status
Full entries
Frequently asked questions
- What is the difference between Lanreotid and LL-37?
- Lanreotid is classified as "Research other", while LL-37 is classified as "Research other". Lanreotid: Lanreotide is a synthetic cyclic octapeptide analog of somatostatin. It binds preferentially to the somatostatin receptors SSTR2 and SSTR5 and is approved for treating acromegaly and certain neuroendocrine tumours. LL-37: LL-37 is the only known human cathelicidin, a 37-amino-acid antimicrobial peptide generated by cleavage of the precursor protein hCAP18. In research it plays a central role in innate immune defence and wound healing, yet acts in a context-dependent manner as both anti- and pro-inflammatory and has been linked to autoimmune processes. LL-37 is not an approved drug; the evidence base is predominantly basic and preclinical. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Lanreotid or LL-37?
- The highest available evidence level is "Human RCT" for Lanreotid and "Human trial" for LL-37. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Lanreotid and LL-37 in Germany and the United States?
- Germany: Lanreotid — Prescription, LL-37 — Research only. United States: Lanreotid — Prescription, LL-37 — Research only. These are factual summaries with source and review date on the individual pages.